ALK-ABELLO B

Danish pharmaceutical company ALK-Abelló on Wednesday raised its full-year financial outlook for 2025, citing strong third-quarter sales of its allergy treatments and adrenaline auto-injectors.

Danish pharmaceutical company ALK on Wednesday raised its full-year financial outlook for 2025 for the third time this year, citing strong business momentum in Europe.

Danish drugmaker ALK has entered a partnership with China-based GenSci to commercialize its house dust mite allergy treatments in mainland China, a deal potentially worth up to 1.3 billion Danish Krone.

Danish drugmaker ALK on Tuesday raised its full-year revenue forecast for 2025, citing stronger-than-expected sales in Europe and an improved outlook for the rest of the year.

Danish drugmaker ALK-Abelló said Friday it has won regulatory approval in the U.K. for its needle-free adrenaline nasal spray used to treat severe allergic reactions.

Danish drugmaker ALK said its adrenaline nasal spray for treating severe allergic reactions produced a response comparable to an adrenaline injection, according to data presented at a European medical conference.